PennLive explains what the change means for thousands of patients, and where GLP-1 medications, diet, exercise and insurance now fit in obesity care.
Recap by typeshit. Full story at PennLive.
Le Figaro reports the tablet arrives in early November. Unlike the Wegovy injection, it won't be covered by France's public reimbursement system.
A TV segment airing on WSIL and KFVS looks at the weight loss drug trend and what coverage people might be able to get through their insurance today.
Monthly units climbed from 114,000 in February to 434,000 in September, and sales value rose from ₹48 cr to ₹113 cr as doctors report wider access.
Lilly is lowering what it charges for one of its weight loss drugs. The headline doesn't say which drug or by how much.
Weight loss may explain much of the knee benefit, but lab work hints at anti-inflammatory and cartilage effects worth a closer read.
The doctor says Medscape quoted their views on where retatrutide fits and how GLP-1 weight loss treatment could change from here.
Loading…